You are here: Industry Insights > Keytruda

News List

Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer contractpharma
July 26, 2021
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
NOXXON Pharma Enters Second Clinical Collaboration With MSD to Evaluate NOX-A12 in Combination With KEYTRUDA (Pembrolizumab) in Upcoming Phase 2 Pancreatic Cancer Study firstwordpharma
July 22, 2021
NOXXON today announced entering into its second clinical collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, N.J. USA), to collaborate in the upcoming Phase 2 clinical trial of NOXXON's NOX-A12 in combination with MSD's anti-PD-1 therapy.
Merck Provides Update on KEYTRUDA® Indication in Third-Line Gastric Cancer americanpharmaceuticalreview
July 05, 2021
Merck announced plans to withdraw the U.S. accelerated approval indication for KEYTRUDA (pembrolizumab) for treatment of patients with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma, with disease progression on or after two or ...
MSD’s Keytruda scores EU approval in certain oesophageal cancer patients pharmatimes
July 02, 2021
MSD’s immunotherapy Keytruda has received approval from the European Commission (EC) in combination with chemotherapy as a first line treatment for certain oesophageal cancer patients.
Merck’s KEYTRUDA Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Cervical Cancer americanpharmaceuticalreview
June 23, 2021
Merck announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with or without bevacizumab ...
Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA(R) in Patients with Advanced Cancer americanpharmaceuticalreview
June 17, 2021
Linnaeus Therapeutics Inc. announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® in Combination With Chemotherapy as First-Line Treatment for Patients With Esophageal Cancer or GEJ Adenocarcinoma americanpharmaceuticalreview
May 25, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum- and ...
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer pharmatimes
May 17, 2021
MSD’s immunotherapy Keytruda has gained UK National Institute for Health and Care Excellence (NICE) backing as a first-line treatment for certain colorectal cancer patients.
Alkermes, Merck Enter Clinical Trial and Supply Agreement contractpharma
April 08, 2021
To evaluate nemvaleukin alfa in combination with Keytruda in patients with platinum-resistant ovarian cancer.
USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA pharmaceutical-business-review
April 02, 2021
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page